Literature DB >> 24165990

[Etiology, diagnosis, management, and treatment of myocarditis. Position paper from the ESC Working Group on Myocardial and Pericardial Diseases].

S Pankuweit1, B Maisch.   

Abstract

Despite great advances in the pathophysiology and etiology of myocarditis, the clinical diagnosis of myocarditis in daily clinical practise remains challenging. Often the diagnosis was not clear because of the heterogeneity of clinical symptoms and the lack of guidelines for adequate diagnostic requirements and consecutive treatment options. The European Society of Cardiology (ESC) Working Group on Myocardial and Pericardial Diseases established a working group of experts to improve the diagnosis and management of myocarditis and to provide a common consensus statement as a reference for future registries and controlled trials. The goal was to bridge the gap between clinical- and tissue-based diagnosis by formulating a concept concerning essential diagnostics and treatment of these patients that would be accepted across Europe. Only in this manner is it possible to establish a basis for national and international registries and double-blind randomized treatment trials for the etiologically differentiated treatment of myocarditis, which appear promising due to numerous studies in recent years. In this paper, two members from the expert working group summarize the most important aspects of this position paper on the etiology, diagnosis, management, and treatment of myocarditis, which were published in the July 2013 issue of European Heart Joumal.

Entities:  

Mesh:

Year:  2013        PMID: 24165990     DOI: 10.1007/s00059-013-3988-7

Source DB:  PubMed          Journal:  Herz        ISSN: 0340-9937            Impact factor:   1.740


  49 in total

Review 1.  Definition of inflammatory cardiomyopathy (myocarditis): on the way to consensus. A status report.

Authors:  B Maisch; I Portig; A Ristic; G Hufnagel; S Pankuweit
Journal:  Herz       Date:  2000-05       Impact factor: 1.443

2.  Immunosuppressive therapy for myocarditis.

Authors:  B Maisch; F Camerini; H P Schultheiss
Journal:  N Engl J Med       Date:  1995-12-21       Impact factor: 91.245

3.  Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC).

Authors:  A John Camm; Paulus Kirchhof; Gregory Y H Lip; Ulrich Schotten; Irene Savelieva; Sabine Ernst; Isabelle C Van Gelder; Nawwar Al-Attar; Gerhard Hindricks; Bernard Prendergast; Hein Heidbuchel; Ottavio Alfieri; Annalisa Angelini; Dan Atar; Paolo Colonna; Raffaele De Caterina; Johan De Sutter; Andreas Goette; Bulent Gorenek; Magnus Heldal; Stefan H Hohloser; Philippe Kolh; Jean-Yves Le Heuzey; Piotr Ponikowski; Frans H Rutten
Journal:  Eur Heart J       Date:  2010-08-29       Impact factor: 29.983

Review 4.  Treatment of inflammatory dilated cardiomyopathy and (peri)myocarditis with immunosuppression and i.v. immunoglobulins.

Authors:  Bernhard Maisch; Günther Hufnagel; Susanne Kölsch; Rainer Funck; Annette Richter; Heinz Rupp; Matthias Herzum; Sabine Pankuweit
Journal:  Herz       Date:  2004-09       Impact factor: 1.443

5.  Immunosuppressive therapy for active lymphocytic myocarditis: virological and immunologic profile of responders versus nonresponders.

Authors:  Andrea Frustaci; Cristina Chimenti; Fiorella Calabrese; Maurizio Pieroni; Gaetano Thiene; Attilio Maseri
Journal:  Circulation       Date:  2003-02-18       Impact factor: 29.690

6.  Two autoimmune diabetes loci influencing T cell apoptosis control susceptibility to experimental autoimmune myocarditis.

Authors:  Mehmet L Guler; Davinna L Ligons; Yan Wang; Michael Bianco; Karl W Broman; Noel R Rose
Journal:  J Immunol       Date:  2005-02-15       Impact factor: 5.422

7.  Predictors of outcome in patients with suspected myocarditis.

Authors:  Ingrid Kindermann; Michael Kindermann; Reinhard Kandolf; Karin Klingel; Burkhard Bültmann; Thomas Müller; Angelika Lindinger; Michael Böhm
Journal:  Circulation       Date:  2008-07-21       Impact factor: 29.690

8.  Usefulness of immunosuppression for giant cell myocarditis.

Authors:  Leslie T Cooper; Joshua M Hare; Henry D Tazelaar; William D Edwards; Randall C Starling; Mario C Deng; Santosh Menon; G Martin Mullen; Brian Jaski; Kent R Bailey; Madeleine W Cunningham; G William Dec
Journal:  Am J Cardiol       Date:  2008-09-18       Impact factor: 2.778

Review 9.  Myocarditis and dilated cardiomyopathy: an inflammatory link.

Authors:  Jay W Mason
Journal:  Cardiovasc Res       Date:  2003-10-15       Impact factor: 10.787

Review 10.  Myocarditis: infection versus autoimmunity.

Authors:  Noel R Rose
Journal:  J Clin Immunol       Date:  2009-11       Impact factor: 8.542

View more
  5 in total

1.  Brazilian Society of Cardiology Guideline on Myocarditis - 2022.

Authors:  Marcelo Westerlund Montera; Fabiana G Marcondes-Braga; Marcus Vinícius Simões; Lídia Ana Zytynski Moura; Fabio Fernandes; Sandrigo Mangine; Amarino Carvalho de Oliveira Júnior; Aurea Lucia Alves de Azevedo Grippa de Souza; Bárbara Maria Ianni; Carlos Eduardo Rochitte; Claudio Tinoco Mesquita; Clerio F de Azevedo Filho; Dhayn Cassi de Almeida Freitas; Dirceu Thiago Pessoa de Melo; Edimar Alcides Bocchi; Estela Suzana Kleiman Horowitz; Evandro Tinoco Mesquita; Guilherme H Oliveira; Humberto Villacorta; João Manoel Rossi Neto; João Marcos Bemfica Barbosa; José Albuquerque de Figueiredo Neto; Louise Freire Luiz; Ludhmila Abrahão Hajjar; Luis Beck-da-Silva; Luiz Antonio de Almeida Campos; Luiz Cláudio Danzmann; Marcelo Imbroise Bittencourt; Marcelo Iorio Garcia; Monica Samuel Avila; Nadine Oliveira Clausell; Nilson Araujo de Oliveira; Odilson Marcos Silvestre; Olga Ferreira de Souza; Ricardo Mourilhe-Rocha; Roberto Kalil Filho; Sadeer G Al-Kindi; Salvador Rassi; Silvia Marinho Martins Alves; Silvia Moreira Ayub Ferreira; Stéphanie Itala Rizk; Tiago Azevedo Costa Mattos; Vitor Barzilai; Wolney de Andrade Martins; Heinz-Peter Schultheiss
Journal:  Arq Bras Cardiol       Date:  2022-07       Impact factor: 2.667

Review 2.  [Inflammatory cardiomyopathy and myocarditis].

Authors:  B Maisch; A D Ristic; S Pankuweit
Journal:  Herz       Date:  2017-06       Impact factor: 1.740

Review 3.  Treatment options in myocarditis and inflammatory cardiomyopathy : Focus on i. v. immunoglobulins.

Authors:  B Maisch; P Alter
Journal:  Herz       Date:  2018-08       Impact factor: 1.443

4.  Successful treatment of fulminant myocarditis with intra-aortic balloon pump counterpulsation combined with immunoglobulin and glucocorticoid in a young male adult.

Authors:  Huanhuan Li; Lun Li
Journal:  Front Cardiovasc Med       Date:  2022-07-22

5.  Glucocorticoid and immunoglobulin to treat viral fulminant myocarditis.

Authors:  Xin Wei; Yuan Fang; Hongde Hu
Journal:  Eur Heart J       Date:  2020-06-07       Impact factor: 29.983

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.